• Transparency in pharmaceutical policy-making would probably lead to increased
confidence in the decision-making process and to better decisions.• In addition to the …

With" Big Pharma" garnering an increasing number of negative headlines due to reports of
adverse drug reactions and a surge in prescription drug addiction and overdose deaths …

The current system of biomedical innovation is unable to keep pace with scientific
advancements. We propose to address this gap by reengineering innovation processes to …

In April 2012, MIT's Center for Biomedical Innovation and the European Medicines Agency
(EMA) cosponsored a workshop on legal foundations of adaptive pharmaceuticals licensing …

The recent approval by the United States Food and Drug Administration of a clinical trial
involving a product derived from human embryonic stem cells, along with recent concerns …

Academic researchers look, in anticipation, toward the possibilities that the common
interoperable electronic health record (EHR) will offer enhanced ability to conduct a wide …

In Canada, databases have been created for the administration of the universal health‐care
program, which covers outpatient and inpatient services. Public prescription drug programs …

Purpose Administrative healthcare utilization data from Canadian provinces have been used
for pharmacoepidemiology and pharmacoeconomics research, but limited transparency …

Aspects of Canada's health regulatory system are currently being reviewed. This is timely, as
the regulation and definition of drugs, foods, and natural health products (NHPs) is in need …

Background Ongoing efforts by Health Canada intended to modernize the legislation and
regulation of pharmaceuticals will help improve the safety and effectiveness of drug …